Intervention Review

You have free access to this content

Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age

  1. Martina Penazzato1,*,
  2. Andrew J. Prendergast2,
  3. Lulu M Muhe3,
  4. Denis Tindyebwa4,
  5. Elaine Abrams5

Editorial Group: Cochrane HIV/AIDS Group

Published Online: 22 MAY 2014

Assessed as up-to-date: 1 NOV 2011

DOI: 10.1002/14651858.CD004772.pub4


How to Cite

Penazzato M, Prendergast AJ, Muhe LM, Tindyebwa D, Abrams E. Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age. Cochrane Database of Systematic Reviews 2014, Issue 5. Art. No.: CD004772. DOI: 10.1002/14651858.CD004772.pub4.

Author Information

  1. 1

    MRC Clinical Trials Unit, London, UK

  2. 2

    Queen Mary University of London, Centre for Paediatrics, Blizard Institute, London, UK

  3. 3

    World Health Organization, Geneva, Switzerland

  4. 4

    African Network for the Care of Children Affected by HIV/AIDS (ANECCA), Kampala, Uganda

  5. 5

    Columbia University. Mailman School of Public Health, Epidemiology and Pediatrics, New York, New York, USA

*Martina Penazzato, MRC Clinical Trials Unit, London, UK. martina.penazzato@gmail.com.

Publication History

  1. Publication Status: Edited (conclusions changed)
  2. Published Online: 22 MAY 2014

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to ongoing studies
  4. Additional references
  5. References to other published versions of this review
Achan 2012 {published and unpublished data}
  • Achan j, Kahuru A, Ikilezi G, Ruel T, Clark T, Charlebois E, Rosenthal P, Dorsey G, Havlir D, Kamya M. Significant Reduction in Risk of Malaria among HIV+ Children Receiving Lopinavir/ritonavir-based ART Compared to NNRTI-based ART, a Randomized Open-label Trial. March 2012; Vol. CROI.
ARROW trial team 2013 {published and unpublished data}
  • ARROW Trial team. Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in Africanchildren with HIV (ARROW): a 5-year open-label randomised factorial trial [Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in Africanchildren with HIV (ARROW): a 5-year open-label randomised factorial trial]. Lancet. 2013 Mar 6;370(12):62198-9.
Coovadia 2010 {published data only}
  • Coovadia A, Abrams EJ, Stehlau R, Meyers T, Martens L, Sherman G, Hunt G, Hu CC, Tsai WY, Morris L, Kuhn L. Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomised controlled trial. JAMA 2010;304(10):1082-90.
Palumbo 2010 {published and unpublished data}
  • Palumbo P, Lindsey JC, Hughes MD, Cotton MF, Bobat R, Meyers T, Bwakura-Dangarembizi M, Chi BH, Musoke P, Kamthunzi P, Schimana W, Purdue L, Eshleman SH, Abrams EJ, Millar L, Petzold E, Mofenson LM, Jean-Philippe P, Violari A. Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med 2010;363(16):1510-20.
Prendergast 2008 (a) {published and unpublished data}
  • Prendergast A, Mphatswe W, Tudor-Williams G, Rakgotho M, Pillay V, Thobakgale C, McCarthy N, Morris L, Walker BD, Goulder P. Early virological suppression with three-class antiretroviral therapy in HIV-infected AFrican infants. AIDS 2008;22(11):1333-43.
Violari 2008 {published data only}
Violari 2012 {published and unpublished data}
  • Violari A,  Lindsey JC,  Hughes MD,  Mujuru HA,  Barlow-Mosha L,  Kamthunzi P,  Chi BH,  Cotton MF,  Moultrie H,  Khadse S,  Schimana W,  Bobat R,  Purdue L, Eshleman SH,  Abrams EJ,  Millar L,  Petzold E,  Mofenson LM,  Jean-Philippe P,  Palumbo P. NVP- vs LPV/r-based ART among HIV+ Infants in Resource-limited Settings: The IMPAACT P1060 Trial [Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children.]. N Engl J Med. 2012 Jun 21; Vol. 366, issue 25:2380-9.
Wamalwa 2012 {published data only (unpublished sought but not used)}
  • Wamalwa D, Benki-Nugent S, Langat A, Tapia K, Ngugi E, Moraa H, Otieno V, Richardson B, Overbaugh J, John-Stewart G. [Treatment Interruption in Infants following 24 Months of Empiric ART: Kenya]. 19th Conference on Retroviruses and Opportunistic Infections- Seattle, Washington State (US). March, 2012.

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to ongoing studies
  4. Additional references
  5. References to other published versions of this review
Ananworanich 2008 {published data only}
  • Ananworanich J, Kosalaraksa P, Siangphoe U, Engchanil C, Pancharoen C, Lumbiganon P, Intasan J, Apateerapong W, Chuenyam T, Ubolyam S, Bunupuradah T, Lange J, Cooper DA, Phanuphak P, HIV-NAT 010 Study Team. A feasibility study of immediate versus deferred antiretroviral therapy in children with HIV infection. AIDS Res Ther 2008;5:24.
Cotton 2012 {published data only}
  • Cotton M, Violari A, Gibb G, Otwombe K, Josipovic D, Panchia R, Jean-Philippe P, Handelsman E, McIntyre J, Babiker A and the CHER Team. Early ART followed by Interruption Is Safe and Is Associated with Better Outcomes than Deferred ART in HIV+ Infants: Final Results from the 6-Year Randomized CHER Trial, South Africa. CROI 2012. March 2012; Vol. 28 LB.
King 2005 {published data only}
  • King JR, Nachman S, Yogev R, Hodge J, Aldrovandi G, Hughes MD, Chen J, Wiznia A, Damle B, Acosta EP. Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403. Pediatr Infect Dis J 2005;24(10):880-5.
Krogstad 2002 {published data only}
  • Krogstad P, Lee S, Johnson G, Stanley K, McNamara J, Moye J, Jackson JB, Aguayo R, Dieudonne A, Khoury M, Mendez H, Nachman S, Wiznia A, Pediatric AIDS Clinical Trials Group 377 Study Team. Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1. Clin Infect Dis 2002;34(7):991-1001.
Lockman 2007 {published data only}
  • Lockman S, Shapiro RL, Smeaton LM, Wester C, Thior I, Stevens L, Chand F, Makhema J, Moffat C, Asmelash A, Ndase P, Arimi P, van Widenfelt E, Mazhani L, Novitsky V, Lagakos S, Essex M. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007;356(2):135-47.
Luzuriaga 2004 {published data only}
  • Luzuriaga K, McManus M, Mofenson L, Britto P, Graham B, Sullivan JL, PACTG 356 Investigators. A trial of three antiretroviral regimens in HIV-1-infected children. N Engl J Med 2004;350(24):2471-80.
NCT00427297 {unpublished data only}
  • John-Stewart G. Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya. Clinicaltrials.gov NCT00427297.
PENPACT1 study team {published data only (unpublished sought but not used)}
  • The PENPACT-1 (PENTA 9/PACTG 390) Study Team. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. The Lancet Infectious Diseases 2011;11(4):273-283.
Prendergast 2008 (b) {published data only}
  • Prendergast A, Chonco F, Tudor-Williams G, Mphatswe W, Cengimbo A, Thobakgale C, Dong C, Coovadia H, Walker B, Goulder P. Randomized controlled trial of 3 approaches to management of HIV-infected infants [Randomized controlled trial of 3 approaches to management of HIV-infected infants]. 16th Conferences on Retroviruses and Opportunistic Infections, Boston, Massachusetts, USA Canada 3-6 February 2008;Abstract 77LB.
Puthanakit 2012 {published data only}
  • Puthanakit T, Saphonn V, Ananworanich J, Kosalaraksa P, Hansudewechakul R, Vibol U, Kerr SJ, Kanjanavanit S, Ngampiyaskul C, Wongsawat J, Luesomboon W, Ngo-Giang-Huong N, Chettra K, Cheunyam T, Suwarnlerk T, Ubolyam S, Shearer WT, Paul R, Mofenson LM, Fox L, Law MG, Cooper DA, Phanuphak P, Chhi Vun M, Ruxrungtham K, on behalf of the PREDICT Study Group. Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre,randomised, open-label trial. The Lancet ID October 9, 2012;S1473-3099(12):70242-6.
Wiznia 2000 {published data only}
  • Wiznia A, Stanley K, Krogstad P, Johnson G, Lee S, McNamara J, Moye J, Jackson JB, Mendez H, Aguayo R, Dieudonne A, Kovacs A, Bamji M, Abrams E, Rana S, Sever J, Nachman S. Combination nucleoside analogue reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial--PACTG 377. Pediatric AIDS Clinical Trials Group 377 Study Team. AIDS Res Hum Retroviruses 2000;16(12):1113-21.
Wongsawat 2010 {published data only}
  • Wongsawat J, Puthanakit T, Kanjanavanit S, Hansudewechakul R, Ngampiyaskul C, Kerr SJ, Ubolyam S, Suwanlerk T, Kosalaraksa P, Luesomboon W, Ngo-Giang-Huong N, Chandara M, Saphonn V, Ruxrungtham K, Ananworanich J, PREDICT Study Group. CD4 cell count criteria to determine when to initiate antiretroviral therapy in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2010;29(10):966-8.

References to ongoing studies

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to ongoing studies
  4. Additional references
  5. References to other published versions of this review
ANRS 12206- MONOD {published data only}
  • Leroy V, Timite-Konan M, Mutabazi V, Meda N. International phase 2b-3 randomized clinical trial to assess two once-daily simplified antiretroviraltriple therapies among HIV-infected children early treated by a 12-month twice daily triple therapybetween 6 weeks and 24 months of age and in virological success in Africa:the MONOD Project(Burkina Faso, Ivory Coast, Rwanda). clinicaltrial.gov NCT01127204.
NCT01146873-NEVEREST 3 {unpublished data only}
  • Treatment Options for Protease Inhibitor-exposed Children (NEVEREST-III). Ongoing study June 2010 (expected completion September 2014).

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to ongoing studies
  4. Additional references
  5. References to other published versions of this review
3Cs4kids 2008
  • Cross Continents Collaboration for Kids (3Cs4kids) Analysis and Writing Committee. Epidemiology and Social Markers for predicting mortality in untreated HIV-infected children in resource-limited settings: a meta-analysis. AIDS 2 January 2008;22(1):97-105. [: http://journals.lww.com/aidsonline/Fulltext/2008/01020/Markers_for_predicting_mortality_in_untreated.12.aspx]
Apollo 2013
  • Apollo T, Zinyowera S, Dzangare J, Chakanyuka C, Mugurungi O, Penazzato M, Martin E, Jordan M, Perriens J, Bertagnolio S. [World Health Organization HIV Drug Resistance surveillance in children less than 18 months newly diagnosed with HIV in Zimbabwe]. 7th IAS Conference in HIV pathogenesis. treatment and prevention. Luala Lumpur, Malaysia. 30 June.
Arpadi 2013
  • Arpadi S, Shiau S, Strehlau R, Martens L, Patel F, Coovadia A, Abrams EJ, Kuhn L. Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy. The Pediatric Infectious Disease Journal 2013;32(1):39-44.
Arrive 2007
  • Arrivé E, Newell ML, Ekouevi DK, Chaix ML, Thiebaut R, Masquelier B, Leroy V, Perre PV, Rouzioux C, Dabis F, Ghent Group on HIV in Women and Children. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis.. Int J Epidemiol 2007 Oct;36(5):1009-21. [: http://www.ncbi.nlm.nih.gov/pubmed/17533166?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=4]
Chatterjee 2010
  • Chatterjee A, Tripathi S, Gass R, Hamunime N, Panha S, Kiyaga C, et al. Implementing services for Early Infant Diagnosis (EID) of HIV: a comparative descriptive analysis of national programs in four countries. BMC Public Health 2010;533(11):2458.
Church 2009
  • Church JD, Mwatha A, Bagenda D, Omer SB, Donnell D, Musoke P, Nakabiito C, Eure C, Bakaki P, Matovu F, Thigpen MC, Guay LA, McConnell M, Fowler MG, Jackson JB, Eshleman SH. In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine.. AIDS Res Hum Retroviruses 2009 Jul;25(7):673-7.. [: http://www.ncbi.nlm.nih.gov/pubmed/19552593?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=3]
DHHS 2011
  • Department of Health and Human Services. Antiretroviral Therapy and Medical Management of HIV- Infected Children. 2011.
Dunn 2008
  • Dunn D, Woodburn P, Duong T, Peto J, Phillips A, Gibb D, Porter K, HIV Paediatric Prognostic Markers Collaborative Study (HPPMCS), Concerted Action on Sero-Conversion to AIDS and Death in Europe (CASCADE) Collaboration. Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults. [Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults.]. J Infect Dis 2008 Feb 1;197(3):398-404. [: http://www.ncbi.nlm.nih.gov/pubmed/18248303?ordinalpos=19&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum]
EPPICC 2011
  • The European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord. Early antiretroviral therapy in HIV-1-infected infants, 1996-2008: treatment response and duration of first-line regimens. AIDS 2011 Nov 28;25(18):2279-2287.
Ferrand 2009
  • Ferrand RA, Corbett EL, Wood R, et al. AIDS among older children and adolescents inSouthern Africa: projecting the time course and magnitude of the epidemic.. AIDS. 2009 Sep 24;23(15):2039-46.
Fillekes 2013
  • Fillekes Q, Mulenga V, Kabamba D, Kankasa C, Thomason MJ, Cook A, Chintu C, Gibb DM, Walker AS, Burger DM, on behalf of the CHAPAS-1 trial team. [Is nevirapine dose escalation appropriate in young African HIV+ children?]. AIDS. 2013 Apr 16 [Epub ahead of print].
Gortmaker 2001
  • Gortmaker SL, Hughes M, Cervia J, Brady M, Johnson GM, Seage GR 3rd, Song LY, Dankner WM, Oleske JM, Pediatric AIDS Clinical Trials Group Protocol 219 Team. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med. 2001 Nov 22;345(21):1522-8.
Griffiths 1976
  • Griffiths R. The Abilities of Babies. University of London Press; A study in mental measurement 1976:pp. 5–44.
Gupta 2012
  • Gupta RK, Jordan MR, Sultan BJ, Hill A, Davis DH, Gregson J, Sawyer AW, Hamers RL, Ndembi N, Pillay D, Bertagnolio S. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet 2012 Oct 6;380(9849):1250-8.
Higgins 2011
  • Higgins J, Green S. Cochrane handbook for systematic reviews of interventions, version 5.1.0. March 2011.
HPPMCS 2003
  • Dunn D, HIV Paediatric Prognostic Markers Collaborative Study Group. Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. [Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis.]. Lancet Nov 15;362(9396):1605-11.. [: http://www.ncbi.nlm.nih.gov/pubmed/14630440]
Hunt 2011
  • Hunt GM, Coovadia A, Abrams EJ, Sherman G, Meyers T, Morris L, Kuhn L. HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine. AIDS 2011 Jul 31;25(12):1461-1469. [: http://www.ncbi.nlm.nih.gov/pubmed/21633285]
Italian Register 1999
  • The Italian Register for HIV Infection in Children. Rapid disease progression in HIV-1 perinatally infected children born to mothers receiving zidovudine monotherapy during pregnancy.. AIDS 1999;13(8):927-33.
Jaquet 2000
  • Jaquet D, Lévine M, Ortega-Rodriguez E, Faye A, Polak M, Vilmer E, Lévy-Marchal C. Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children. AIDS 2000 Sep 29;14(14):2123-8.. [: http://www.ncbi.nlm.nih.gov/pubmed?term=jaquet%202000%20HIV]
Karchava 2006
  • Karchava M, Pulver W, Smith L, Philpott S, Sullivan TJ, Wethers J, Parker MM.SourceWadsworth Center, New York State Department of Health, Albany, NY 12201-2002, USA. Prevalence of drug-resistance mutations and non-subtype B strains among HIV-infected infants from New York State. J Acquir Immune Defic Syndr 2006 Aug 15;42(5):614-9. [: http://www.ncbi.nlm.nih.gov/pubmed/16868498?ordinalpos=3&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]
Kinabo 2013
Kuhn 2012
  • Kuhn L, Coovadia A, Strehlau R, Meyers T, Martens L, Sherman G, Hunt G, Tsai W-T, Morris L, Ambrams E. Long-term Outcomes of Switching Children to NVP-based Therapy after Initial Suppression with a PI-based Regimen.
Kuhn 2013
  • Kuhn L, Hunt G, Technau K, Coovadia A, Black V, Morris L, Abrams E. and Finding Infants with HIV Disease and Evaluating Resistance Study Group. [Pre-treatment Drug Resistance Mutations among HIV+ Children <2 Years of Age Who Failed or Missed PMTCT: Johannesburg, South Africa]. 20th Conference on Retroviruses and Opportunistic Infections- Atlanta, Georgia. 3-6 March 2013; Vol. Abstract 951.
Laughton 2012
  • Laughton B, Cornell M, Grove D, Kidd M, Springer PE, Dobbels E, van Rensburg AJ, Violari A, Babiker AG, Madhi SA, Jean-Philippe P, Gibb DM, Cotton MF. Early antiretroviral therapy improves neurodevelopmental outcomes in infants. AIDS 2012 Aug 24;24(13):1685-90.
Lewis 2012
  • Lewis J, Walker AS, Castro H, De Rossi A, Gibb DM, Giaquinto C, Klein N, Callard R. Age and CD4 count at initiation of antiretroviral therapy in HIV-infected children: effects on long-term T-cell reconstitution.. J Infect Dis 2012 Feb 15;205(4):548-56..
Lindsey 2012
  • Lindsey J, Hughes M, A Violari, Eshleman S, Abrams E, Mofenson L, Jean-Philippe P, Palumbo P and P1060 Study Team . Predictors of Virologic and Clinical Response to Nevirapine- vs Lopinavir/ritonavir-based ART in Infants and Children with and without Prior Nevirapine Exposure for the PMTCT. CROI 2012. March 2012; Vol. paper 25.
Lockman 2007
  • Lockman S, Shapiro RL, Smeaton LM, Wester C, Thior I, Stevens L, Chand F, Makhema J, Moffat C, Asmelash A, Ndase P, Arimi P, van Widenfelt E, Mazhani L, Novitsky V, Lagakos S, Essex M. Response to Antiretroviral Therapy after a Single, Peripartum Dose of Nevirapine. N Engl J Med January 11, 2007, (356):135-147. [: http://www.nejm.org/doi/full/10.1056/NEJMoa062876]
Luiz 2001
  • Luiz D, Foxcroft C, Stewart R. The construct validity of the Griffiths Scales of Infant Development.. Child: care health and development. 2001;27:73–83.
Martinson 2007
  • Martinson NA, Morris L, Gray G, Moodley D, Pillay V, Cohen S, Dhlamini P, Puren A, Bhayroo S, Steyn J, McIntyre JA. J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):148-53.Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine.. J Acquir Immune Defic Syndr 2007 Feb 1;44(2):148-53. [: http://www.ncbi.nlm.nih.gov/pubmed/17117145?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=16]
McComsey 2002
  • McComsey G. Update on mitochondrial toxicity of antiretrovirals and its link to lipodystrophy.. AIDS Rev 2002 Jul-Sep;4(3):140-7. [: http://www.ncbi.nlm.nih.gov/pubmed/12416448]
McIntosh 1996
  • McIntosh K, Shevitz A, Zaknun D, Kornegay J, Chatis P, Karthas N, Burchett SK. .Age- and time-related changes in extracellular viral load in children vertically infected by human immunodeficiency virus. Pediatr Infect Dis J 1996 Dec;15(12):1087-91. [: http://www.ncbi.nlm.nih.gov/pubmed/8970217?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=91]
Mphatswe 2007
  • Mphatswe W, Blanckenberg N, Tudor-Williams G, Prendergast A, Thobakgale C, Mkhwanazi N, McCarthy N, Walker BD, Kiepiela P, Goulder P. High frequency of rapid immunological progression in African infants infected in the era of perinatal HIV prophylaxis.. AIDS 2007;21(10):1253-61.
Mulenga 2010
  • Mulenga V, Cook A, Walker AS, Kabamba D, Chijoka C, Ferrier A, Kalengo C, Kityo C, Kankasa C, Burger D, Thomason M, Chintu C, Gibb DM. Strategies for nevirapine initiation in HIV-infected children taking pediatric fixed-dose combination "baby pills" in Zambia: a randomized controlled trial.. Clin Infect Dis. 2010 Nov 1;51(9):1081-9.
Musiime 2009
  • Musiime V, Ssali F, Kayiwa J, Namala W, Kizito H, Kityo C, Mugyenyi P. Response to nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-infected children with perinatal exposure to single-dose nevirapine. AIDS Res Hum Retroviruses 2009 Oct;25(10):989-96. [: http://www.ncbi.nlm.nih.gov/pubmed/19778270]
Newell 2004
  • Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F, Ghent International AIDS Society (IAS) Working Group on HIV Infection in Women and Children. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis.. Lancet 2004 Oct 2-8;364(9441):1236-43.
NIAID 2009
  • United States National Institute of Allergy and Infectious Diseases (NIAID). Division of AIDS, Table for Grading Adult and Pediatric Adverse Events (Toxicity Table),dated December 2004 (Clarification August 2009) [Available from: hiv.cochrane.org/sites/hiv.cochrane.org/files/uploads/Table_for_Grading_Severity_of_Adult_Pediatric_Adverse_Events.pdf].
PENTA 11
  • Paediatric European Network for Treatment of AIDS. Response to planned treatment interruptions in HIV infection varies across childhood. AIDS 2010 Jan 16;24(2):231-41.
PENTA 2002
  • Paediatric European Network for Treatment of AIDS (PENTA). Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial [Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial]. Lancet 2002 Mar;2(359(9308)):733-40.
PENTA 2009
Persaud 2007
  • Persaud D, Palumbo P, Ziemniak C, Chen J, Ray SC, Hughes M, Havens P, Purswani M, Gaur AH, Chadwick EG, Pediatric AIDS Clinical Trials Group P1030 Team. Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States.. J Infect Dis 2007 May 15;195(10):1402-10.. [: http://www.ncbi.nlm.nih.gov/pubmed/17436219?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]
Persaud 2013
  • Persaud D, Gay H, Ziemniak C, Chen YH, Piatak M, Chun TW, Strain M, Richman D, Luzuriaga K. Absence of Detectable HIV-1 Viremia after Treatment Cessation in an Infant.. N Engl J Med.. 2013 Oct 23..
Pillay 2008
  • Pillay V, Ledwaba J, Hunt G, Rakgotho M, Singh B, Makubalo L, Bennett DE, Puren A, Morris L. Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004. Antivir Ther. ; 2008;13(Suppl 2):101-7. [: http://www.ncbi.nlm.nih.gov/pubmed/18575198]
Piloya 2012
  • Piloya T, Bakeera-Kitaka S, Kekitiinwa A, et al. Lipodystrophy among HIV-infected children and adolescents on highly active antiretroviral therapy in Uganda: a cross sectional study.. Journal of the International AIDS Society 2012;15(2):17427.
Prendergast 2012
  • Prendergast AJ, Penazzato M, Cotton M, Musoke P, Mulenga V, Abrams EJ, Gibb DM. Treatment of young children with HIV infection: using evidence to inform policymakers [Treatment of young children with HIV infection: using evidence to inform policymakers]. PLoS Med 2012;9(7):e1001273.
Ruel 2013
  • Ruel T, Kakuru A, Ikilezi G, Mwangwa F, Dorsey G, Rosenthal P, Charlebois E, Havlir D, Kamya M, Achan J. [Comparison of Virologic and Immunologic Outcomes between HIV+ Ugandan Children Randomized to Ritonavir-boosted Lopinavir or NNRTI- based ART]. 20th Conference on Retroviruses and Opportunistic Infections- Atlanta, Georgia, USA.. 3-6 March 2013; Vol. Abstract 88 LB.
UNAIDS 2012
  • UNAIDS. UNAIDS Report on the global AIDS epidemIc 2012. http://www.unaids.org/en/resources/campaigns/20121120_globalreport2012/globalreport/ 2012.
Vigano 2003
  • Viganò A, Mora S, Testolin C, Beccio S, Schneider L, Bricalli D, Vanzulli A, Manzoni P, Brambilla P. Increased lipodystrophy is associated with increased exposure to highly active antiretroviral therapy in HIV-infected children. J Acquir Immune Defic Syndr 2003 Apr 15;32(5):482-9. [: http://www.ncbi.nlm.nih.gov/pubmed/12679698]
Wade 1994
  • Wade AM, Ades AE. Age-related reference ranges: significance tests for models and confidence intervals for centiles. Stat Med 1994 Nov 30;13(22):2359-67.. [: http://www.ncbi.nlm.nih.gov/pubmed/7855469?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=2]
Walker 2004
  • Walker AS, Doerholt K, Sharland M, Gibb DM, Collaborative HIV Paediatric Study (CHIPS) Steering Committee. Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study. AIDS 2004 Sep 24;18(14):1915-24. [: http://www.ncbi.nlm.nih.gov/pubmed/15353977?ordinalpos=27&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum]
WHO 2010
  • WHO. Antiretroviral therapy for HIV infection in infants and children: Recommendations for a public health approach (2010 revision). 2010; Vol. http://www.who.int/hiv/pub/guidelines/paediatric020907.pdf.
WHO 2011
  • WHO 2011. GLOBAL HIV/AIDS RESPONSE. Epidemic update and health sector progress towards Universal Access. Progress Report 2011. [: http://whqlibdoc.who.int/publications/2011/9789241502986_eng.pdf]
WHO 2013
  • World Health Organisation. Consolidated Guidelines on the use of Antiretroviral drugs for treating and preventing HIVinfection. June 2013.

References to other published versions of this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to ongoing studies
  4. Additional references
  5. References to other published versions of this review
Penazzato 2012
  • Penazzato M, Prendergast A, Tierney J, Cotton M, Gibb D. Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age. Cochrane Database of Systematic Reviews 2012 Jul 11, Issue 7. [PUBMED: 22786492]